SEPTEMBER 19 , 2019
NAMWOLF Annual Meeting 2019
Quick Links

Drinker Biddle & Reath LLP

Foley & Lardner LLP
Greenberg Traurig, LLP

Keller and Heckman LLP

Farrone Advisors
National Law Review Legal Industry News
Publish with NLR
Cannabis, Biotech, Food and Drug Legal News
In house attorneys looking for a better way to organize, vet and easily retrieve legal news created the National Law Review on-line edition.

Around the clock, the National Law Review's editors screen and classify breaking news and analysis authored by recognized legal professionals and our own journalists.

There is no log in to access the database and new articles are added hourly.
On September 11, 2019 President Trump, along with HHS Secretary Azar and FDA Commissioner Sharpless, announced that the Food and Drug Administration (FDA) intends to soon finalize a compliance policy to prioritize enforcement of the premarket authorization requirements against non-tobacco flavored e-cigarettes. E-cigarettes on the market as of August 8, 2016, the effective date of FDA’s “Deeming Rule”, are currently allowed to be marketed until Premarket Tobacco Product Applications (PMTAs) are due – the deadline for which has shifted numerous times over the years, and is currently set for May 11, 2020. See American Academy of Pediatrics v. FDA. More on FDA's Removal of Flavored E-Cigarettes Here  >
Eight drug retailers, distributors, and pharmacies (but no manufacturers) have asked Judge Dan Aaron Polster to recuse himself from presiding over most of the 2,000 pending opioid lawsuits comprising the MDL.
The parties filed the motion to disqualify Judge Polster on Saturday. They claim that the Judge’s comments made during various hearings, interviews, and forums demonstrate prejudice and bias.
The defendants emphasized comments during the first MDL hearing on January 9th, 2018: because of the “opioid crisis. 150 Americans are going to die today, just today, while we’re meeting.” “My objective is to do something meaningful to abate this crisis,” Judge Polster added.More on the Opioid MDL Litigation Here >
Much of the regulatory "attention" regarding cannabidiol ("CBD") has been, understandably, focused on the U.S. Food and Drug Administration ("FDA"). 
Indeed, the FDA was the first federal regulatory agency to publicly comment on the decriminalization of hemp and CBD in the 2018 Farm Bill.  But the FDA is not alone in this universe.  The Federal Trade Commission ("FTC") also has a role to play in the monitoring of health-related advertising claims made in connection with CBD products.
 More on FTC's Warning on Unsupported CBD Claims  Here >
U.S. Judge Janis L. Sammartino in California’s Southern District certified a price fixing class action against “Big Tuna” this summer following a Daubert review of experts, keeping with Ninth Circuit precedent and focusing on the rigorousness of the review of expert reliability, but not the admissibility of evidence.
This is just one in a growing line of cases that address the propriety of a Daubert review at the class certification stage, a country-wide discussion following the cryptic message handed down from the Supreme Court in Wal-Mart Stores, Inc. v. Dukes, 131 S. Ct. 2541 (2011): “The District Court concluded that Daubert did not apply to expert testimony at the certification stage of class-action proceedings. We doubt that is so.”
 More on the Big Tuna Price Fixing Suit Here >
Please let other interested professionals know about this valuable and free resource!

If you know someone interested in publishing with the National Law Review, kindly contact us at:
The National Law Review
National Law Forum, LLC
Jennifer Schaller, Esq.
NatLawReview Newsletters
NLR Publication Areas
The National Law Review
 708-357-3317 | jschaller@natlawreview.com | www.natlawreview.com
4700 Gilbert Avenue Suite #47 #230
Western Springs, IL 60558